Carbon ion radiotherapy with complete tumor regression for primary malignant melanoma of female uret

Carbon ion radiotherapy with complete tumor regression for primary malignant melanoma of female urethra orifice: a case report

Xiaojun Li, Yihe Zhang, Yanshan Zhang, Yancheng Ye, Ying Qi, Tingchao Hu and Xin Pan

Abstract

Primary malignant melanoma of the female urethra (PMMFU) is extremely rare, accounting for 0.2% of all melanomas, and fewer than 200 cases have been reported worldwide. Because of the small number of clinical cases and unclear biological characteristics, there is no uniform and standard treatment protocol. We herein describe the treatment of PMMFU using carbon ion radiotherapy. The radiotherapy was delivered at 60.8Gy (RBE) in 16 fractions, once daily, five times per week. The patient achieved complete tumor disappearance within 1 year after carbon ion radiotherapy and remained disease-free thereafter. She developed acute grade ¹ radiation dermatitis and urethritis, which resolved quickly; no other toxic effects were observed. At the time of this writing, her survival duration was 33 months. This case demonstrates that carbon ion radiotherapy may be a good option for primary genitourinary mucosal malignancies.

Introduction

Malignant melanoma (MM) is a highly malignant tumor of melanocytes that occurs in the skin, mucosa, and uvea.¹ Mucosal MM (MMM) is a rare malignant tumor of mucosal origin, accounting for approximately 1% of all MMs.² MMM occurring in the nasal cavity, oral cavity, and lip mucosa is rare; moreover, primary MM of the female urethra (PMMFU) is extremely rare,³ accounting for 0.2% of all melanomas.⁴ Because of the extremely small number of clinical cases of urethral MM and unclear biological characteristics, no consensus has been reached regarding the optimal treatment protocol. Most oncologists recommend radical resection, and classic radical surgery comprises partial vulvectomy and total urethrectomy (including resection of the anterior vaginal wall and bladder neck) with inguinal lymph node dissection. Additional procedures may include pelvic lymph node dissection, reconstruction of the urethra using a bladder muscle flap, and even anterior hemipelvic radical surgery.⁵ However, such invasive treatments deprive patients of their normal functions.Nevertheless, management of PMMFU recurrence remains challenging, and a local recurrence rate of up to 60% to 70% at 1 year after surgery has been reported.⁶

Radiotherapy is an effective local treatment for patients with inoperable tumors and those who are reluctant to undergo surgery. However, MMM is usually is an X-ray-resistant tumor.⁷ Carbon ion radio-therapy (CIRT) has distinct physical characteristics, including a sharp lateral penumbra, very low energy deposition within the entry path prior to the Bragg peak formed by the steep dose deposition, and a sharp dose fall-off after the Bragg peak, thus facilitating dose delivery within a finite range.⁸ In addition to its superior physical properties, CIRT is a modality with high linear energy transfer, and the relative biological effectiveness (RBE) of CIRT is significantly higher than that of photon and proton radiation. The RBE value is 2 to 5 for CIRT depending on the tissue type and endpoint of study. It has been suggested that more damage from radiation with high linear energy transfer occurs in the form of direct DNA double-strand breaks, which is more difficult to repair.⁹ These properties together are beneficial in treating tumors that are not sensitive to X-ray radiation. CIRT for urothelial melanoma has rarely been reported. We herein describe a patient with PMMFU who underwent CIRT, achieved complete tumor disappearance within 1 year after completion of CIRT,and remained disease-free thereafter; at the time of this writing, her survival period was 33 months. This case is reported in accordance with the CARE guidelines.¹⁰

Case presentation

Figure 1.​​ (a) Malignant melanoma of the urethral orifice was observed. (b) Cystoscopy showed a dark brown mass of about 3cm in the urethral orifice. (c) Microphotograph (×100) from a fine needle aspiration biopsy specimen showed characteristic malignant melanoma cells.

​​Figure 2.​​ Images of the urethral orifice melanoma. (a) Positron emission tomography/computed tomography imaging. Before treatment, a high standardized uptake value was observed. (b) Diffusion-weighted imaging demonstrated a high-intensity lesion. (c) T1-weighted contrast-enhanced sagittal imaging also demonstrated a high-intensity lesion. (d) Coronal magnetic resonance imaging.

A woman in her early 70s was referred to our center to undergo CIRT for a urethral orifice MM. In the latter half of 2018, she had experienced discomfort and a swelling sensation of the urethral orifice while performing physical activity, and these symptoms were accompanied by urinary frequency and urgency. The symptoms gradually became aggravated during the next 3 months. Soon thereafter, a nontender, dark brown, indurated mass resembling a plum was found at the urethral orifice (Figure 1(a)). During the following 3 months, the mass progressively enlarged and the patient developed dysuria and a burning sensation during urination. At the end of 2018, cystoscopy at a local hospital showed an approximately 3-cm dark brown mass at the urethral orifice (Figure 1(b)). Pathological examination of a needle biopsy specimen showed MM, and immunohistochemical examination showed CKP (-), HMB45 (-), S-100 (-), melan-A (+), vimentin (+), CD30 (-), and Ki-67 (+70%) (Figure 1(c)). Fluorodeoxyglucose-positron emission tomography/computed tomography (CT) showed abnormally increased fluorodeoxyglucose uptake in the urethral orifice (29 × 26 × 26mm) with a maximum standardized uptake value of 48.6 (Figure 2(a)).

Magnetic resonance imaging (MRI) showed a round high-intensity lesion at the urethral orifice on T2-weighted imaging, similar to the findings on T1-weighted imaging and diffusion-weighted imaging (Figure 2(b–d)), with an apparent diffusion coefficient of 0.88×10⁻³ mm²/s and significant enhancement (Figure 2(c) and (d)). On gynecologic examination, a round mass was found at the urethral orifice at the 6-o’clock position with the patient in the lithotomy position. The lesion invaded the vaginal wall, measured approximately 2.5 × 2.4 × 2.0cm, and was dark brown and hard on palpation. It had a smooth surface and limited mobility, no tenderness, no obvious ulcer or bleeding, and no purulent secretion. The diagnosis was urethral MM cT4aN0M0 IIb (Revised American Joint Committee on Cancer 2002 tumor-node-metastasis melanoma staging system).¹¹ The patient had no cancer-related family history. She refused to undergo surgical treatment, so she was transferred to our center for CIRT. The patient was immobilized in the lithotomy position and underwent CT simulation using a four-dimensional CT system with 3-mm-thick slices. Treatment planning was performed using the ciPlan system, version 1.0 (Institute of Modern Physics, Lanzhou, China). The target area was delineated on the CT images. The gross target volume was the urethral orifice mass on CT, fused with the MRI and positron emission tomography/CT images. The clinical target volume included the gross target volume plus a 5-mm margin to encompass the surrounding tissue at risk of microscopic involvement. The planning target volume consisted of the clinical target volume plus an isotropic 3-mm margin for positioning errors during daily radiotherapy.

A passive scattered carbon ion beam (Heavy Ion Medical Machine; Lanzhou Kejin Taiji Corporation, Ltd.) was used for the treatment. CIRT planning was performed using biologic treatment plan optimization by the ciPlan treatment planning software system, which takes into account local values of the RBE calculated by the ciPlan software based on the mixed beam model. The mixed beam model was developed to predict the RBE of the passively scattered carbon ion beams with the tumor response as the relevant endpoint. The calculated radiation dose for the target volume and surrounding normal structures was expressed as the Gy RBE-weighted dose, which was defined as the physical dose multiplied by the carbon ion RBE, which is approximately 3.0 at 0.8cm from the distal end of the spread-out Bragg peak.

Figure 3. Carbon ion radiotherapy target and dose distribution.

CIRT was delivered at a 60.8-Gy RBE-weighted dose in 16 fractions with a 190-MeV/U carbon ion beam, once daily, five times per week (Monday to Friday) for 22 days using one vertical portal (Figure 3).

Efficacy was evaluated according to the RECIST 1.1 criteria.¹² Acute reactions of normal tissue were classified according to the Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 4.0,¹³ with a maximum reaction occurring within 3 months after initiation of therapy. Late reactions were classified according to the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer scoring system.¹⁴

Figure 4. Skin and mucosa reactions at 10, 30, and 60 days after the start of carbon ion radiotherapy.

Table 1 CIRT,  Evaluation of efficacy according to maximum diameter of tumor.

CIRT, carbon ion radiotherapy; SD, stable disease; PR, partial response; CR, complete response.

Figure 5.  Comparison of imaging data before carbon ion radiotherapy, 90 days after carbon ion radiotherapy (partial response), and  180 days after carbon ion radiotherapy (partial response).

Figure 6.  Gadolinium-enhanced magnetic resonance imaging  1 year after carbon ion radiotherapy showed that the lesion had completely disappeared.

During  CIRT,  dysuria  and  frequency (up to 9–10 times/day)  occurred from the seventh fraction of treatment. These symptoms were  considered  to  have  been  caused  by radiation-induced urethral edema, and they were relieved by symptomatic treat ment.  Skin  and  mucosal  erythema  in  the irradiated field occurred  10 days after the start  of CIRT,  as did edema  of the labia major  and  minor,  the  vaginal opening, and the urethral orifice around the lesion; these were assessed as grade 1 radiation dermatitis and mucositis. The skin and mucosal  adverse  effects were relieved 1 month after completion of CIRT, and the dermatitis, mucositis,  dysuria,  and  frequency  of urination were totally  resolved  2 months after completion  of CIRT  (Figure 4). No other  acute or chronic  adverse  effects of CIRT were observed. At the end of CIRT, the  tumor treatment  response  was  stable disease. Three months after completion of CIRT, the lesion was visually smaller than before,  and  MRI  showed  that  the  maximum  tumor  diameter  was   about 17mm with  a  32%  reduction  (partial  remission). The  lesion  completely  disappeared 1 year after  treatment  (Table 1,  Figure 5,  and Figure  6). The patient declined  other  systemic  treatment  after  CIRT  for  personal reasons. As of November 2021, 33 months after   CIRT,   the  patient  was   alive   and disease-free. She was satisfied with the outcome  of CIRT.  No  severe  reactions were observed.

Discussion

PMMFU accounts for 0.2% of all melanomas and 4% of all urothelial carcinomas. Fewer than 200 cases have been reported in the literature.^15,16 About 50% of mucosal melanomas  occur  in  the  head  and  neck region (nasal cavity, sinuses, and oropharynx), about 30% occur in the gastrointestinal  tract (esophagus, rectum, and  analcanal), and approximately 20% involve the   genitourinary tract (vagina, cervix, bladder, and urethra); mucosal melanomas occasionally originate from other mucosal areas.¹⁷ Clinical manifestations of PMMFU include a  mass  of  the  urethra, hematuria,  and  urinary  tract  obstruction. Our patient presented with a mass in the external  urethral orifice with   a   typical dark brown appearance.

Urethral  tumors  are  among  the  rarest types  of  cancer  in  the  female  urogenital tract. Cystourethroscopy permits visualiza- tion of urethral tumors and facilitates biop- sies  for  histological  examination.  MRI  is recommended  for  tumor  staging.  Local, superficial, and distal urethral tumors may be treated by partial resection with preservation of the urethra. Radical urethrectomy and wide resection of  the paraurethral tissues   and   anterior vaginal  wall may offer superior local control of this disease. However, advanced female urethral tumors and  lymph  node  positivity are associated with a poor prognosis for all survival outcomes (recurrence-free, cancer-specific, and overall survival). Multimodal therapy including surgery, chemotherapy, and radiotherapy are required in modern management  regimens,  although  the  specific role and combination of each treatment is less clearly determined. Wide resection after chemotherapy and/or radiotherapy is asso- ciated  with  the  best  local  control,  but  it reduces the patient’s quality of life.¹⁸

There is no standard treatment protocol for urothelial MM, but most experts recommend radical resection.¹⁷  However, because of the complex anatomy and delicate phys- iological function of the urogenital tract in which the tumor is located, achieving R0 resection with surgical  treatment  is often  challenging  and  is  likely  to  result in the loss of  physiological  function. Furthermore, the recurrence rate of urothelial  MM  is  as  high  as 71% regardless  of the  surgical  approach.¹⁷  Davuluri  et  al.⁶  described a patient with a 49-mm PMMFU who developed recurrence and metastasis 5 months after surgical treatment. The patient underwent salvage pelvic radiotherapy and immunotherapy and eventually died of metastatic  disease 11 months  after  surgery.⁶  Broussard et al.¹⁹ described an 87-year-old woman with urethral MM who underwent extensive local tumor resection and achieved postoperative survival of only 3 months.

Radiation therapy is a widely used and effective  local  treatment  for many  malignant tumors, and it is often the only alternative local treatment available for patients not amenable to surgery. However, MMM is resistant  to  X-ray radiation.  The radiation-resistant  nature  of  melanoma results  in  limited  efficacy  of conventional radiation in the  treatment of  MMM. CIRT is a highly precise radiation therapy technique because of its physical properties. It  also  provides  higher  RBE  that  can  be used for the treatment of malignancies resistant to photon radiation. In addition, early results  of  clinical  studies  have  suggested that  such  advantages might  translate into improved clinical outcomes.20 CIRT exhibits improved treatment outcomes in tumors resistant to photon radiotherapy including melanoma,  osteosarcoma, chondrosarcoma,  chordoma,  and  other soft  tissue sarcomas.²¹

A systematic review of the effectiveness and   safety  of  CIRT  for  MM  reported pooled data from  11 studies, showing that patients   with   MM   treated  with  CIRT exhibited  better  local  control,  low  recur- rence rates, and mild toxicity at sites includ- ing  the skin,   mucosa,  and   choroid.22 Murata  et  al.23    examined  the  long-term treatment  outcomes  of CIRT  for  gyneco- logic MM with tumor sites in the vagina vulva,  and  uterus  and  observed  complete tumor  disappearance in  30  of 37 patients (81%); the 2-year local control, overall survival,  and  progression-free   survival  rates were  71%,   53%,  and  29%,  respectively. These results  are encouraging for  MM in the  genitourinary  tract  and  conform  to our experience in this case report. Because PMMFU is very rare, there is no standard protocol  for  CIRT,  and  very  few  reports have described prophylactic irradiation  of lymph  nodes  using  CIRT.  Therefore,  our multidisciplinary team decided to perform CIRT only for the primary tumor; regional lymph node irradiation was not performed.

Wuwei Heavy Ion Center is a carbon ion facility in China dedicated to medical use and was  designed by the Institute   of Modern  Physics  of the  Chinese  Academy of Sciences. We used  this facility  to  treat tumors    since November 2018.24  Few reports worldwide have described patients who underwent  CIRT  for  treatment  of PMMFU. In the present case, we treated one  patient with CIRT  and  achieved  a good outcome with no adverse events. At the  time  of  this  writing,  the  patient  was disease-free with a survival duration of 33 months after CIRT.

Our report  demonstrates  that complete tumor regression is possible after CIRT in patients with PMMFU.  Longer follow-up and larger numbers of patients are needed to further assess the long-term effectiveness and late toxicity-related adverse effects  of this treatment.

Ethics statements

This  study was  approved  by  the  ethics  review committee of Wuwei Cancer Hospital. Written informed consent was obtained from the patient.

Declaration of conflicting interest

The authors declare that there is no conflict of interest.

Funding

The  authors  disclosed  receipt  of the  following financial  support  for  the  research,  authorship, and publication of this article: This  study was supported  by  the  Key  R&D  Plan  of  Science and  Technology  Program  of  Gansu  Province, China (no. 19YF3FH001).

ORCID iD

Yanshan Zhang  https://orcid.org/0000-0003- 4621-148X

References

1.  Kibbi N, Kluger  H, and   Choi JN. Melanoma:  clinical  presentations.  Cancer Treat Res 2016; 167: 107–129.

2. Jawad MB and Kofoed K. Mucosal malig- nant melanomas in the gastrointestinal tract and urogenital organs. Ugeskr Laeger 2017; 179: V09160679.

3.  Barnhill RL and Gupta K. Unusual variants of   malignant   melanoma.  Clin  Dermatol 2009; 27: 564–587.

4.  Safadi A, Schwalb S, Ben-Shachar I, et al. Primary  malignant urethral  melanoma resembling  a  urethral  caruncle.  Urol  Case Rep 2017; 15: 28–29.

5.  Todo  Y,  Okamoto  K,  Suzuki  Y,  et  al. Radicality  of  initial   surgery  for  primary malignant  melanoma  of  the vagina. Melanoma Res 2016; 26: 173–180.

6.  Davuluri  M, Long  B, Semple  S,  et   al. Primary  urethral melanoma: a  case report and literature review.  Urology 2019; 126: 1–4.

7.  Qin J, Li S, Zhang C, et al. Apoptosis and injuries of heavy ion beam and x-ray radia- tion on malignant melanoma cell. Exp Biol Med (Maywood) 2017; 242: 953–960.

8.  Lin  R,  Slater  JD,  Yonemoto   LT,  et  al. Nasopharyngeal  carcinoma:  repeat   treat- ment   with  conformal   proton   therapy— dose-volume histogram  analysis.  Radiology 1999; 213: 489–494.

9.  Huang  YW,  Pan   CY,  Hsiao  YY,   et  al. Monte Carlo simulations of the relative bio- logical effectiveness for DNA double strand

breaks from 300MeVu1 carbon-ion beams. Phys Med Biol 2015; 60: 5995–6012.

10.  GagnierJJ, Kienle G, Altman DG, et al. The CARE  guidelines:  consensus-based  clinical case reporting guideline development. Headache 2013; 53: 1541–1547.

11. Piura B. Management of primary melanoma of the female urogenital tract. Lancet Oncol 2008; 9: 973–981.

12.  Eisenhauer EA, Therasse P, BogaertsJ, et al. New  response  evaluation  criteria  in  solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–247.

13. NCI   Common   Terminology   Criteria   for Adverse Events (CTCAE) V4.0 Data Files. Available  online: http:  //evs.nci.nih.gov/ ftp1/CTCAE/About.html (accessed  15 January 2019).

14.  Cox JD, Stetz J and Pajak TF. Toxicity cri- teria  of  the  Radiation  Therapy  Oncology Group (RTOG) and  the European Organization  for  Research  and  Treatment of  Cancer  (EORTC).  Int  J  Radiat  Oncol Biol Phys 1995; 31: 1341–1346.

15. Walsh PC, Retik AB, McDougal WC, et al. Surgery  of penile  and  urethral  carcinoma. In:  Wein  AJ,  Kavoussi  LR,  Novick  AC, et  al.  (eds)  Campbell-Walsh   Urology.  10th ed.    Philadelphia:    WB    Saunders,    2012. pp.946–951.

16.  El-Safadi   S,   Estel   R,   Mayser   P, et   al. Primary  malignant  melanoma  of  the  ure- thra: a systematic analysis of the current lit- erature.  Arch   Gynecol  Obstet  2014;  289: 935–943.

17.  Kalogirou EM, Kalyvas D, Tosios KI, et al. Recurrence in a patient with a  10-year his- tory of sinonasal mucosal melanoma mani- festing  as facial  swelling. J Clin Exp Dent 2017; 9: e1492–e1495.

18.  Dell’Atti L and Galosi AB. Female urethra adenocarcinoma. Clin Genitourin Cancer 2018; 16: e263–e267.  doi: 10.1016/j. clgc.2017.10.006

19.  Broussard AP, Chaudoir C and Gomelsky A. Urethral melanoma in  an  elderly woman. Int Urogynecol J 2015; 26: 149–150.

20.  Habermehl  D,  Wagner  M,  Ellerbrock  M, et  al.  Reirradiation  using  carbon  ions  in patients with locally recurrent rectal cancer at HIT: first results. Ann Surg Oncol 2015; 22: 2068–2074.

21.  Kamada  T,  Tsujii  H,  Blakely  EA,  et  al. Policy  Review Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience. Lancet Oncol 2015; 16: e93–e100.

22.  Li  C,  Zhang  Q,  Li  Z,  et  al.  Efficacy  and safety  of  carbon-on  radiotherapy  for  the malignant melanoma: A systematic review. Cancer Med 2020; 9: 5293–5305.

23.  Murata H, Okonogi N, Wakatsuki M, et al. Long-term  outcomes  of  carbon-ion  radio- therapy  for  malignant  gynecological  mela- noma. Cancers (Basel) 2019; 11: 482.

24.  Li  X,  Zhang  Y,  Ye  Y,  et  al.  Carbon  ion radiotherapy for recurrent calf myxoid lip- osarcoma: a case report. J Int Med Res 2021; 49: 3000605211009701.

初审：张莉红      复审：张洁